Lake Success, NY - Protocol Builder, the cloud-based solution for investigator-initiated clinical trials, is now available to individual researchers, including medical residents and fellows, according to the Biomedical Research Alliance of New York (BRANY), the developer of the system.
“Residents and fellows are often challenged with developing research protocols that meet IRB and regulatory requirements,” says Raffaella Hart, Vice President, IRB and IBC Services. “Protocol Builder provides an easy-to-navigate solution that guides individuals writing research protocols through an intelligent step-by-step process, saving time and effort.”
The tool, originally developed as an enterprise solution, provides simple instructions and relevant tips developed by experts. A built-in Resource Center allows investigators to access protocol samples as well as links to important educational and regulatory information. Users can also download commonly used forms.
With a cloud-based solution, collaboration is easy. Investigators can invite others to review and add comments directly to the appropriate sections.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.